

**Brilliant Violet 421™ anti-human CD20**

**Catalog # / Size:** 2111645 / 25 tests  
2111650 / 100 tests

**Clone:** 2H7

**Isotype:** Mouse IgG2b, κ

**Immunogen:** Human tonsillar B cells


**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 421™ and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

**Workshop Number:** IV B201

**Concentration:** Lot-specific




Human peripheral blood lymphocytes were stained with CD19 PE and CD20 (clone 2H7) Brilliant Violet 421™ (top) or mouse IgG2b, κ Brilliant Violet 421™ isotype control (bottom).

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.



Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent

applications and foreign equivalents.

**Application Notes:** The epitope recognized by clone 2H7 has been mapped to the sequence YNCEPANPSEKNSPST which lies in the large extracellular loop of human CD20. Additional reported applications (for the relevant formats) include: immunoprecipitation<sup>4</sup> and immunohistochemical staining of acetone-fixed frozen sections<sup>5</sup>.

**Application References:**

1. Schlossman S, *et al.* 1995. *Leucocyte Typing V*. Oxford University Press. New York.
2. Knapp W, *et al.* 1989. *Leucocyte Typing IV*. Oxford University Press. New York.
3. McMichael A, *et al.* Eds. 1987. *Leucocyte Typing III* Oxford University Press. New York.
4. Polyak MJ, *et al.* 2002. *Blood* 99:3256. (IP)
5. Mack CL, *et al.* 2004. *Pediatr. Res.* 56:79. (IHC)
6. Du J, *et al.* 2014. *Cancer Immunol Res.* 2:878. [PubMed](#)

---

**Description:** CD20 is a 33-37 kD, four transmembrane spanning protein, also known as B1 and Bp35. CD20 is expressed on pre-B-cells, resting and activated B cells (not plasma cells), some follicular dendritic cells, and at low levels on a T cell subset. CD20 is heavily phosphorylated on activated B cells and malignant B cells. Homooligomeric complexes of CD20 are thought to form Ca<sup>2+</sup> conductive ion channels in the plasma membrane of B cells. The CD20 molecule is involved in B-cell activation and is associated with various Src family kinases (Lyn, Lck, Fyn). It exists in a complex with MHC class I and II, CD53, CD81, and CD82.

**Antigen References:**

1. Hultin L, *et al.* 1993. *Cytometry* 14:196.
2. Tedder T, *et al.* 1994. *Immunol. Today* 15:450.